Cargando…

Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets

Objectives. We evaluated the ingestibility and formulation quality of one branded (formulation A) and five generic (formulations B, C, D, E, and F) lansoprazole orally disintegrating (OD) tablets. Methods. Ingestibility, including the oral disintegrating time, taste, mouth feeling, and palatability,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chono, Sumio, Matsui, Megumi, Nakamura, Katsuki, Kasai, Ryoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156814/
https://www.ncbi.nlm.nih.gov/pubmed/28044122
http://dx.doi.org/10.1155/2016/6131608
_version_ 1782481329564155904
author Chono, Sumio
Matsui, Megumi
Nakamura, Katsuki
Kasai, Ryoya
author_facet Chono, Sumio
Matsui, Megumi
Nakamura, Katsuki
Kasai, Ryoya
author_sort Chono, Sumio
collection PubMed
description Objectives. We evaluated the ingestibility and formulation quality of one branded (formulation A) and five generic (formulations B, C, D, E, and F) lansoprazole orally disintegrating (OD) tablets. Methods. Ingestibility, including the oral disintegrating time, taste, mouth feeling, and palatability, was examined by sensory testing in healthy subjects. Formulation qualities, including salivary stability, gastric acid resistance, and intestinal dissolution behavior, were examined. Results and Discussion. The oral disintegration time of formulation F (52 s) was significantly longer than that of other formulations (32–37 s). More than 90% of subjects did not experience bitterness with formulations A, E, and F, whereas 50% of subjects felt rough and powdery sensations with formulations B, C, and D. More than 80% of subjects suggested that formulations A, E, and F had good palatability. Ingestibility was different between formulations. OD tablets consist of enteric granules containing lansoprazole, which is unstable in gastric acid. Enteric granules of each formulation were stable in artificial saliva and gastric juice. No differences were observed in dissolution behaviors among the formulations, indicating that the formulation quality of the formulations was almost equivalent. Conclusions. This study provides useful information for selecting branded or generic lansoprazole OD tablets for individualized treatments.
format Online
Article
Text
id pubmed-5156814
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-51568142017-01-02 Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets Chono, Sumio Matsui, Megumi Nakamura, Katsuki Kasai, Ryoya J Pharm (Cairo) Research Article Objectives. We evaluated the ingestibility and formulation quality of one branded (formulation A) and five generic (formulations B, C, D, E, and F) lansoprazole orally disintegrating (OD) tablets. Methods. Ingestibility, including the oral disintegrating time, taste, mouth feeling, and palatability, was examined by sensory testing in healthy subjects. Formulation qualities, including salivary stability, gastric acid resistance, and intestinal dissolution behavior, were examined. Results and Discussion. The oral disintegration time of formulation F (52 s) was significantly longer than that of other formulations (32–37 s). More than 90% of subjects did not experience bitterness with formulations A, E, and F, whereas 50% of subjects felt rough and powdery sensations with formulations B, C, and D. More than 80% of subjects suggested that formulations A, E, and F had good palatability. Ingestibility was different between formulations. OD tablets consist of enteric granules containing lansoprazole, which is unstable in gastric acid. Enteric granules of each formulation were stable in artificial saliva and gastric juice. No differences were observed in dissolution behaviors among the formulations, indicating that the formulation quality of the formulations was almost equivalent. Conclusions. This study provides useful information for selecting branded or generic lansoprazole OD tablets for individualized treatments. Hindawi Publishing Corporation 2016 2016-12-01 /pmc/articles/PMC5156814/ /pubmed/28044122 http://dx.doi.org/10.1155/2016/6131608 Text en Copyright © 2016 Sumio Chono et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chono, Sumio
Matsui, Megumi
Nakamura, Katsuki
Kasai, Ryoya
Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets
title Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets
title_full Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets
title_fullStr Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets
title_full_unstemmed Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets
title_short Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets
title_sort ingestibility and formulation quality of lansoprazole orally disintegrating tablets
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156814/
https://www.ncbi.nlm.nih.gov/pubmed/28044122
http://dx.doi.org/10.1155/2016/6131608
work_keys_str_mv AT chonosumio ingestibilityandformulationqualityoflansoprazoleorallydisintegratingtablets
AT matsuimegumi ingestibilityandformulationqualityoflansoprazoleorallydisintegratingtablets
AT nakamurakatsuki ingestibilityandformulationqualityoflansoprazoleorallydisintegratingtablets
AT kasairyoya ingestibilityandformulationqualityoflansoprazoleorallydisintegratingtablets